Catalog No.
RHB24001
Species reactivity
Human, Mouse, Rat, Hamster
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IF: 1:50-1:200, IHC: 1:50-1:100, WB: 1:500-1:1000
Target
SAP 155, SAP155, SF3B1, Pre-mRNA-splicing factor SF3b 155 kDa subunit, Splicing factor 3B subunit 1, Spliceosome-associated protein 155, SF3b155
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O75533
Applications
IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1F47
Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China., PMID:40474348
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes., PMID:40334184
Association of Specific Gene Mutations with Immunoglobulin Heavy-Chain Variable Region and Chromosomal Alterations in Chronic Lymphocytic Leukemia Patients in India., PMID:39873992
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept., PMID:39644054
Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis., PMID:39251642
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)., PMID:38654616
Chronic Lymphocytic Leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing., PMID:38175592
Targeting transforming growth factor beta signaling in metastatic osteosarcoma., PMID:38021074
Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer., PMID:38012150
Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review., PMID:37551557
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia., PMID:37511096
Activation of distinct inflammatory pathways in subgroups of LR-MDS., PMID:37420006
[Clinical analysis of 20 cases of small B lymphocyte proliferative disease with t (14;19) (q32;q13)]., PMID:36709153
STEREOTYPED CASES IN UKRAINIAN COHORT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DEPENDING ON THE IONIZING RADIATION EXPOSURE., PMID:36582097
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience., PMID:35392224
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)., PMID:34506616
The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients., PMID:34492598
[Chronic lymphocytic leukemia with t (14;18) (q32;q21) : report of eight cases and a literature review]., PMID:34455745
Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3., PMID:34442029
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation., PMID:34265801
The protein landscape of chronic lymphocytic leukemia., PMID:34189564
How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma., PMID:33922591
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2., PMID:33801781
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients., PMID:33730841
Development of luspatercept to treat ineffective erythropoiesis., PMID:33687432
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes., PMID:33539200
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics., PMID:33211804
Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications., PMID:32720348
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax., PMID:32206772
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes., PMID:32179032
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial., PMID:32015491
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia., PMID:31849198
Pathophysiology of chronic lymphocytic leukemia and human B1 cell development., PMID:31797231
Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia., PMID:31230372
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience., PMID:31054420
Analysis of LPL gene expression in patients with chronic lymphocytic leukemia., PMID:30932419
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab., PMID:30842083
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion., PMID:30712845
Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment., PMID:30686074
THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT., PMID:30582853
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group., PMID:30203893
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses., PMID:30022491
Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma., PMID:29954402
Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers., PMID:29796163
Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients., PMID:29745034
Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation., PMID:29367434
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients., PMID:29365086
Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia., PMID:28994094
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL., PMID:28925785
A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors., PMID:28892161
For research use only. Not for human or drug use.
